Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioGaia AB ( ($SE:BIOG.B) ) just unveiled an announcement.
BioGaia reported a strong fourth quarter of 2025, with net sales rising 21% to SEK 440.6 million and organic growth of 32%, driven by robust gains in both Pediatrics and Adult Health. Operating profit increased 17% to SEK 121 million, profit after tax climbed 21%, and key R&D milestones included publication of results on its patented L. reuteri BG-R46 strain and a discovery, together with the University of Gothenburg, linking gut bacteria to serotonin production.
For full-year 2025, net sales grew 8% to SEK 1,538.2 million with 14% organic growth, but operating profit slipped 3% and the operating margin narrowed to 27% as higher operating expenses weighed on earnings. Despite lower full-year profit and a reduced total dividend proposal of SEK 4.00 per share, BioGaia’s strong Q4 performance exceeded market expectations and underscores continued demand for its probiotic portfolio, while the board also earmarked funds for charitable donations, including to a foundation aimed at preventing antibiotic resistance.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK125.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia AB is a Swedish publicly listed company specializing in probiotic products, with a strong focus on pediatric and adult health segments. The company develops and markets clinically documented probiotic strains and formulations, targeting gastrointestinal health and related conditions in children and adults worldwide.
Average Trading Volume: 300,500
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK11.15B
For a thorough assessment of BIOG.B stock, go to TipRanks’ Stock Analysis page.